Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
Background. Anti-PD-1 antibodies (anti-PD-1) have clinical activity in a number of malignancies. All clinical trials have excluded patients with significant pr
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2017
|
| In: |
Annals of oncology
Year: 2016, Volume: 28, Issue: 2, Pages: 368-376 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw443 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1093/annonc/mdw443 Verlag, Volltext: https://academic.oup.com/annonc/article/28/2/368/2669811 
|
| Author Notes: | A.M. Menzies, D.B. Johnson, S. Ramanujam, V.G. Atkinson, A.N.M. Wong, J.J. Park, J.L. McQuade, A.N. Shoushtari, K.K. Tsai, Z. Eroglu, O. Klein, J.C. Hassel, J.A. Sosman, A. Guminski, R.J. Sullivan, A. Ribas, M.S. Carlino, M.A. Davies, S.K. Sandhu, G.V. Long |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1581322828 | ||
| 003 | DE-627 | ||
| 005 | 20220815021300.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180926r20172016xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdw443 |2 doi | |
| 035 | |a (DE-627)1581322828 | ||
| 035 | |a (DE-576)511322828 | ||
| 035 | |a (DE-599)BSZ511322828 | ||
| 035 | |a (OCoLC)1341019389 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Menzies, Alexander |e VerfasserIn |0 (DE-588)1167881230 |0 (DE-627)1031400656 |0 (DE-576)511322607 |4 aut | |
| 245 | 1 | 0 | |a Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab |c A.M. Menzies, D.B. Johnson, S. Ramanujam, V.G. Atkinson, A.N.M. Wong, J.J. Park, J.L. McQuade, A.N. Shoushtari, K.K. Tsai, Z. Eroglu, O. Klein, J.C. Hassel, J.A. Sosman, A. Guminski, R.J. Sullivan, A. Ribas, M.S. Carlino, M.A. Davies, S.K. Sandhu, G.V. Long |
| 264 | 1 | |c 2017 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published: 29 September 2016 | ||
| 500 | |a Gesehen am 26.09.2018 | ||
| 520 | |a Background. Anti-PD-1 antibodies (anti-PD-1) have clinical activity in a number of malignancies. All clinical trials have excluded patients with significant pr | ||
| 534 | |c 2016 | ||
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 28(2017), 2, Seite 368-376 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab |
| 773 | 1 | 8 | |g volume:28 |g year:2017 |g number:2 |g pages:368-376 |g extent:9 |a Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/annonc/mdw443 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/annonc/article/28/2/368/2669811 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180926 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |e 910000PH129790702 |e 911300PH129790702 |k 0/910000/ |k 1/910000/911300/ |p 12 | ||
| 999 | |a KXP-PPN1581322828 |e 3027254987 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1581322828"],"doi":["10.1093/annonc/mdw443"]},"name":{"displayForm":["A.M. Menzies, D.B. Johnson, S. Ramanujam, V.G. Atkinson, A.N.M. Wong, J.J. Park, J.L. McQuade, A.N. Shoushtari, K.K. Tsai, Z. Eroglu, O. Klein, J.C. Hassel, J.A. Sosman, A. Guminski, R.J. Sullivan, A. Ribas, M.S. Carlino, M.A. Davies, S.K. Sandhu, G.V. Long"]},"recId":"1581322828","physDesc":[{"extent":"9 S."}],"title":[{"title_sort":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab"}],"note":["Published: 29 September 2016","Gesehen am 26.09.2018"],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"display":"Menzies, Alexander","role":"aut","given":"Alexander","family":"Menzies"},{"role":"aut","given":"Jessica C.","family":"Hassel","display":"Hassel, Jessica C."}],"relHost":[{"pubHistory":["1.1990 -"],"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}],"part":{"text":"28(2017), 2, Seite 368-376","extent":"9","issue":"2","pages":"368-376","volume":"28","year":"2017"},"id":{"eki":["320428796"],"issn":["1569-8041"],"zdb":["2003498-2"]},"origin":[{"publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedKey":"1990","dateIssuedDisp":"1990-","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford"}],"title":[{"subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology","title":"Annals of oncology"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"320428796","physDesc":[{"extent":"Online-Ressource"}],"disp":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabAnnals of oncology"}],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"2017"}]} | ||
| SRT | |a MENZIESALEANTIPD1THE2017 | ||